Goal of Launching 10 New Therapies by 2027
Plans to Enter the CAR-T Field in Korea Next Year
"Advancing R&D and Improving Treatment Accessibility Together"

"If I had to choose a single keyword that encapsulates how Gilead Korea has been able to grow, I would say it is 'challenge.' This means the challenge of breaking through in the most difficult and treatment-limited areas, the challenge of going beyond existing therapies to set new standards of treatment, and the challenge of being a social partner in creating better treatment environments for patients and the broader communities they belong to."


Choi Jaeyeon, CEO of Gilead Sciences Korea, described the company's past 15 years in these terms at a press conference marking its 15th anniversary, held on the 22nd at The Plaza Hotel in Jung-gu, Seoul. She added, "Going forward, our first priority is to continue taking on the challenge of addressing life-threatening diseases with high unmet needs through science, without losing our original purpose. Even with effective drugs, if they do not reach patients, they become meaningless, so improving treatment accessibility remains an ongoing issue that must be solved."


The press conference, held under the theme "15 Years of Gilead Korea Making the Impossible Possible," provided an opportunity to review the achievements of developing and supplying therapeutics in Korea and to share future directions for research and development (R&D).


Choi Jaeyeon, President of Gilead Sciences Korea, is speaking at a press conference commemorating the 15th anniversary of Gilead Korea, held on the 22nd at The Plaza Hotel in Jung-gu, Seoul. Gilead Sciences Korea

Choi Jaeyeon, President of Gilead Sciences Korea, is speaking at a press conference commemorating the 15th anniversary of Gilead Korea, held on the 22nd at The Plaza Hotel in Jung-gu, Seoul. Gilead Sciences Korea

View original image

Since the establishment of its local corporation in 2011, Gilead Korea has supplied 12 therapeutic products in areas such as liver disease, HIV, antifungal agents, and oncology. The company considers it especially significant that it has raised treatment goals for diseases with limited available options.


For example, hepatitis C, once a disease requiring prolonged treatment and associated with a high burden of side effects, has now become a condition where a cure can be expected in over 95% of cases. HIV, which once threatened survival, has now developed into a condition that can be managed long-term with just a single pill per day, significantly expanding treatment possibilities.


Recently, the company has also expanded its focus to oncology. In triple-negative breast cancer, it has broadened treatment options, which were previously centered on chemotherapy, by introducing antibody-drug conjugates (ADC). In hematologic malignancies such as diffuse large B-cell lymphoma (DLBCL), it is developing CAR-T therapies.


Korea has established itself as a major clinical hub for Gilead's global new drug development. More than 40% of the global clinical trials being conducted by Gilead currently involve Korea, and when focusing on oncology trials, Korea's participation rate reaches approximately 60%.


Going forward, the company plans to further expand its business from its traditional strengths in viral diseases to the oncology and inflammatory disease areas. Gilead's headquarters has set a goal of launching about 10 new treatments in the global market by 2027.


Choi said, "In Korea, we are planning to enter the CAR-T field next year. Not only will we address the existing viral and oncology fields, but we will also newly enter the inflammatory disease field, striving to deliver treatments as quickly as possible to patients with unmet needs."


She continued, "What a pharmaceutical company must do is prove, based on scientific and medical evidence, how valuable its treatments are by demonstrating both efficacy and safety with data. At the same time, we must continue to work with various partners to generate new ideas for improving accessibility."


Panel discussion is underway at the Gilead Sciences Korea 15th Anniversary Press Conference held on the 22nd at The Plaza Hotel in Jung-gu, Seoul. From left to right: Junwoo Ban, Director of the Clinical Trial Center at Asan Medical Center, Kyunghoon Lee, Professor of Hematology-Oncology at Seoul National University Hospital, Seunghwan Kim, Executive Director of Sinnaneun Center, and Jaeyeon Choi, CEO of Gilead Korea. Gilead Sciences Korea

Panel discussion is underway at the Gilead Sciences Korea 15th Anniversary Press Conference held on the 22nd at The Plaza Hotel in Jung-gu, Seoul. From left to right: Junwoo Ban, Director of the Clinical Trial Center at Asan Medical Center, Kyunghoon Lee, Professor of Hematology-Oncology at Seoul National University Hospital, Seunghwan Kim, Executive Director of Sinnaneun Center, and Jaeyeon Choi, CEO of Gilead Korea. Gilead Sciences Korea

View original image

The press conference also brought together clinical researchers, healthcare professionals, and representatives from civil society communities, providing an opportunity to look back on changes in Korea's treatment environment over the past 15 years from their respective perspectives. Panelists included Junwoo Ban, Director of the Clinical Trial Center at Asan Medical Center; Kyunghoon Lee, Professor of Hematology-Oncology at Seoul National University Hospital; Seunghwan Kim, Executive Director of Sinnaneun Center; and CEO Choi.


They agreed that, in order to extend the benefits of scientific innovation to more domestic patients, it is essential to pair the development of innovative therapies with advancements in the research and clinical environment, improved treatment accessibility, and increased social awareness.



Choi stated, "I understand that the word 'cure' represents an extraordinary goal, but it remains our objective. While focusing on treatment, we also strive for prevention and will continue to seek new therapies that can increase the possibility of a cure beyond existing treatments, as this is the direction Gilead must take."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing